Evotec (EVT) Q3 2024 earnings summary

Executive summary

• 2024 marked a pivotal year with a comprehensive transformation program, including a Priority Reset targeting €40 million in annual savings, operational excellence, and a strategic review for long-term profitable growth.

• Strategic collaborations expanded with Sandoz, Novo Nordisk, BMS, Bayer, and Pfizer, supporting growth in cell therapy and biosimilars.

• Grand opening of the J.POD biologics facility in Toulouse and strong performance at Just – Evotec Biologics.

• Priority reset and reorganization progressing, including site closures, headcount reduction, and cost optimization, with about one-third of footprint reduction completed.

• Guidance for full-year 2024 confirmed despite challenging market and overcapacity.

Financial highlights

• Nine-month group revenues reached €575.7 million, down 1% year-over-year, with Shared R&D revenue declining 12% and Just – Evotec Biologics growing 74% to €128.7 million.

• Adjusted group EBITDA for nine months was -€6 million, with Just – Evotec Biologics above breakeven at €0.8 million.

• Gross margin improved from 8.6% in Q2 to 9.8% in Q3, driven by Just – Evotec Biologics.

• Positive free cash flow of €16.7 million in Q3, with liquidity increasing to €303.3 million, supported by R&D tax credit factoring.

• Net loss widened to €155.2 million from €67.8 million in 9M 2023, mainly due to higher costs and reorganization expenses.

Outlook and guidance

• 2024 guidance confirmed: group revenues expected between €790–820 million, R&D expenditure €50–60 million, and adjusted EBITDA of €15–35 million.

• Substantial profit uplift anticipated in Q4 from increased revenues and ramp-up of cost savings.

• No guidance for 2025 provided; a new strategy will be unveiled in April 2025.